Shares in Senseonics (NYSE:SENS) closed down -3% yesterday after the medical device maker met earnings expectations on Wall Street with its fourth quarter and full-year financial results, but narrowly missed sales estimates. The Germantown, Md.-based company posted a net loss of -$16.3 million, or -12¢ per share, on sales of $2.9 million for the 3 months ended […]
Diabetes
Judge rips into Abbott’s diabetes test strip supplier over discovery fraud
A supplier that sells an international version of Abbott‘s (NYSE:ABT) FreeStyle Diabetes test strips committed discovery fraud when it forked over only a select group of relevant documents last year, according to a U.S. magistrate judge. Lois Bloom ruled that the supplier, H&H, lost the right to invoke attorney-client privilege when it is deposed about […]
Medtronic wins FDA nod for connected, predictive CGM system
Medtronic (NYSE:MDT) said today that its Guardian Connect continuous glucose monitoring system won FDA approval for people with diabetes ages 14 to 75. The medtech titan touted its system as the first connected standalone CGM designed to help people with diabetes avoid high and low glucose events. Using Medtronic’s Guardian Sensor 3, the system alerts its […]
Insulet nabs spot as in-network provider with UnitedHealthcare
Insulet (NSDQ:PODD) and UnitedHealthcare (NYSE:UNH) inked a new network relationship last week, giving people enrolled in UnitedHealthcare’s commercial and Medicaid plans in-network coverage for Insulet’s Omnipod insulin delivery device. “Through this new relationship, we are working together to help people access the insulin management technology they need to effectively manage their diabetes,” the companies wrote in a […]
Valeritas takes on multiple daily insulin injections with wearable V-Go device
There are millions of Americans with Type II diabetes and many of them take multiple daily injections of insulin, using two injection pens – one for mealtime insulin and one for insulin throughout the day. But studies have found that people with Type II diabetes are willing to skip insulin injections if they have to […]
Patent board upholds AgaMatrix’s CGM patents in Dexcom IP spat
The legal back and forth between Dexcom (NSDQ:DXCM) and AgaMatrix over the companies’ continuous glucose monitoring IP dates back to March of 2016, when AgaMatrix launched a patent infringement lawsuit against the San Diego, Calif.-based manufacturer in the U.S. District Court of Oregon. Later that year, Dexcom filed for inter parters review with the Patent Trial […]
Preparing for commercial launch, Nemaura boosts manufacturing capabilities
Nemaura Medical (NSDQ:NMRD) plans to expand into new manufacturing facilities in preparation for the commercial launch of its non-invasive glucose monitoring system. The company expects to win CE Mark approval for its sugarBeat system in the coming months and also hopes to launch additional trials in the U.S. to support a regulatory bid with the FDA. […]
Tandem Diabetes sales up 40% in Q4
Shares in Tandem Diabetes Care (NSDQ:TNDM) rose yesterday after the insulin pump maker beat expectations on Wall Street with its fourth quarter and full-year results. The San Diego Calif.-based company reeled in its losses in Q4, posting a net loss of -$11.4 million on sales of $40.3 million for the 3 months ended Dec. 31, for […]
FDA panel to review Senseonics’ implantable CGM this month
A panel for the FDA is slated to review Senseonics‘ (NYSE:SENS) premarket approval application for its Eversense implantable continuous glucose monitoring system on March 29. The company’s device sends glucose data every five minutes to a transmitter, which then communicates that information to a mobile app, displaying the values in the real-time. The Eversense system […]
Dexcom beats The Street with Q4 sales, earnings
Dexcom (NSDQ:DXCM) beat expectations on Wall Street with its fourth quarter and full year financial results, growing its quarterly revenue 29% compared to the same period last year. The San Diego, Calif.-based company posted a net loss of -$9.4 million, or -11¢ per share, on sales of $221 million for the 3 months ended Dec. 31. […]